WW domain-containing oxidoreductase's role in myriad cancers: Clinical significance and future implications

Experimental Biology and Medicine

Volumn 239, Issue 3, 2014, Pages 253-263

  Gardenswartz, Aliza ^a   Aqeilan, Rami I ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

breast cancer; hypermethylation; lung cancer; tumor suppressor gene; WW domain containing oxidoreductase

Indexed keywords

ESTROGEN RECEPTOR; OXIDOREDUCTASE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CARCINOGENICITY; CELL GROWTH; COLORECTAL CANCER; DISEASE FREE SURVIVAL; GENE DELETION; GENE EXPRESSION; GENOMIC INSTABILITY; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HYBRIDIZATION; LUNG CANCER; MUTATION; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; TUMOR GROWTH; TUMOR INVASION; UBIQUITINATION; UPREGULATION;

BREAST CANCER; HYPERMETHYLATION; LUNG CANCER; TUMOR SUPPRESSOR GENE; WW DOMAIN-CONTAINING OXIDOREDUCTASE;

ANIMALS; CELL PROLIFERATION; DNA METHYLATION; FEMALE; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MICE; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOPLASMS; OXIDOREDUCTASES; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84896035949     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213519213     Document Type: Article

References (103)

1. Salah Z,Aqeilan R,Huebner K.WWOX gene and gene product: tumor suppression through specific protein interactions.Future Oncol. 2010;6:249-59.
2. Bednarek AK,Laflin KJ,Daniel RL,Liao Q,Hawkins KA,Aldaz CM.WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.Cancer Res. 2000;60:2140-45.
3. Ried K,Finnis M,Hobson L,Mangelsdorf M,Dayan S,Nancarrow JK,Woollatt E,Kremmidiotis G,Gardner A,Venter D,Baker E,Richards RI.Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells.Hum Mol Genet. 2000;9:1651-63.
4. Chang NS,Pratt N,Heath J,Schultz L,Sleve D,Carey GB,Zevotek N.Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity.J Biol Chem. 2001;276:3361-70.
5. Beroukhim R,Mermel CH,Porter D,Wei G,Raychaudhuri S,Donovan J,Barretina J,Boehm JS,Dobson J,Urashima M,Mc Henry KT,Pinchback RM,Ligon AH,Cho YJ,Haery L,Greulich H,Reich M,Winckler W,Lawrence MS,Weir BA,Tanaka KE,Chiang DY,Bass AJ,Loo A,Hoffman C,Prensner J,Liefeld T,Gao Q,Yecies D,Signoretti S,Maher E,Kaye FJ,Sasaki H,Tepper JE,Fletcher JA,Tabernero J,Baselga J,Tsao MS,Demichelis F,Rubin MA,Janne PA,Daly MJ,Nucera C,Levine RL,Ebert BL,Gabriel S,Rustgi AK,Antonescu CR,Ladanyi M,Letai A,Garraway LA,Loda M,Beer DG,True LD,Okamoto A,Pomeroy SL,Singer S,Golub TR,Lander ES,Getz G,Sellers WR,Meyerson M.The landscape of somatic copy-number alteration across human cancers.Nature. 2010;463:899-905.
6. Watanabe A,Hippo Y,Taniguchi H,Iwanari H,Yashiro M,Hirakawa K,Kodama T,Aburatani H.An opposing view on WWOX protein function as a tumor suppressor.Cancer Res. 2003;63:8629-33.
7. Chang NS,Schultz L,Hsu LJ,Lewis J,Su M,Sze CI.17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo.Oncogene. 2005;24:714-23.
8. Fabbri M,Iliopoulos D,Trapasso F,Aqeilan RI,Cimmino A,Zanesi N,Yendamuri S,Han SY,Amadori D,Huebner K,Croce CM.WWOX gene restoration prevents lung cancer growth in vitro and in vivo.Proc Natl Acad Sci U S A. 2005;102:15611-6.
9. Iliopoulos D,Fabbri M,Druck T,Qin HR,Han SY,Huebner K.Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression.Clin Cancer Res. 2007;13:268-74.
10. Qin HR,Iliopoulos D,Semba S,Fabbri M,Druck T,Volinia S,Croce CM,Morrison CD,Klein RD,Huebner K.A role for the WWOX gene in prostate cancer.Cancer Res. 2006;66:6477-81.
11. Becker S,Markova B,Wiewrodt R,Hoffarth S,Hahnel PS,Pleiner S,Schmidt LH,Breitenbuecher F,Schuler M.Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer.J Thorac Oncol. 2011;6:1976-83.
12. Gourley C,Paige AJ,Taylor KJ,Ward C,Kuske B,Zhang J,Sun M,Janczar S,Harrison DJ,Muir M,Smyth JF,Gabra H.WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.Cancer Res. 2009;69:4835-42.
13. Aqeilan RI,Trapasso F,Hussain S,Costinean S,Marshall D,Pekarsky Y,Hagan JP,Zanesi N,Kaou M,Stein GS,Lian JB,Croce CM.Targeted deletion of Wwox reveals a tumor suppressor function.Proc Natl Acad Sci U S A. 2007;104:3949-54.
14. Abdeen SK,Salah Z,Maly B,Smith Y,Tufail R,Abu-Odeh M,Zanesi N,Croce CM,Nawaz Z,Aqeilan RI.Wwox inactivation enhances mammary tumorigenesis.Oncogene. 2011;30:3900-6.
15. Ludes-Meyers JH,Kil H,Nunez MI,Conti CJ,Parker-Thornburg J,Bedford MT,Aldaz CM.WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy.Genes Chromosomes Cancer. 2007;46:1129-36.
16. Aqeilan RI,Croce CM.WWOX in biological control and tumorigenesis.J Cell Physiol. 2007;212:307-10.
17. Chang NS,Hsu LJ,Lin YS,Lai FJ,Sheu HM.WW domain-containing oxidoreductase: a candidate tumor suppressor.Trends Mol Med. 2007;13:12-22.
18. Del Mare S,Salah Z,Aqeilan RI.WWOX: its genomics, partners, and functions.J Cell Biochem. 2009;108:737-45.
19. Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation.Cell. 2011;144:646-74.
20. Ekizoglu S,Muslumanoglu M,Dalay N,Buyru N.Genetic alterations of the WWOX gene in breast cancer.Med Oncol. 2012;29:1529-35.
21. Liu CJ,Shen WG,Peng SY,Cheng HW,Kao SY,Lin SC,Chang KW.miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene.Int J Cancer.
22. Yendamuri S,Kuroki T,Trapasso F,Henry AC,Dumon KR,Huebner K,Williams NN,Kaiser LR,Croce CM.WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer.Cancer Res. 2003;63:878-81.
23. Aqeilan RI,Kuroki T,Pekarsky Y,Albagha O,Trapasso F,Baffa R,Huebner K,Edmonds P,Croce CM.Loss of WWOX expression in gastric carcinoma.Clin Cancer Res. 2004;10:3053-8.
24. Paige AJ,Taylor KJ,Taylor C,Hillier SG,Farrington S,Scott D,Porteous DJ,Smyth JF,Gabra H,Watson JE.WWOX: a candidate tumor suppressor gene involved in multiple tumor types.Proc Natl Acad Sci U S A. 2001;98:11417-22.
25. Guo W,Dong Z,Dong Y,Guo Y,Kuang G,Yang Z.Genetic and epigenetic alterations of WWOX in the development of gastric cardia adenocarcinoma.Environ Mol Mutagen. 2013;54:112-23.
26. Finnis M,Dayan S,Hobson L,Chenevix-Trench G,Friend K,Ried K,Venter D,Woollatt E,Baker E,Richards RI.Common chromosomal fragile site FRA16D mutation in cancer cells.Hum Mol Genet. 2005;14:1341-9.
27. Singh V,Sharma P,Capalash N.DNA methyltransferase inhibitors as epigenetic therapy for cancer.Curr Cancer Drug Targets.
28. Iliopoulos D,Guler G,Han SY,Johnston D,Druck T,McCorkell KA,Palazzo J,McCue PA,Baffa R,Huebner K.Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.Oncogene. 2005;24:1625-33.
29. Wang X,Chao L,Jin G,Ma G,Zang Y,Sun J.Association between CpG island methylation of the WWOX gene and its expression in breast cancers.Tumour Biol. 2009;30:8-14.
30. Severe N,Dieudonne FX,Marie PJ.E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.Cell Death Dis. 2013;4:e463-e463.
31. Mahajan NP,Whang YE,Mohler JL,Earp HS.Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox.Cancer Res. 2005;65:10514-23.
32. Kesson EM,Allardice GM,George WD,Burns HJ,Morrison DS.Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women.BMJ. 2012;344:e2718-e2718.
33. Higginbotham KS,Breyer JP,McReynolds KM,Bradley KM,Schuyler PA,Plummer WD,Freudenthal ME,Trentham-Dietz A,Newcomb PA,Parl FF,Sanders ME,Page DL,Egan KM,Dupont WD,Smith JR.A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24.Cancer Epidemiol Biomarkers Prev. 2012;21:1565-73.
34. Abdeen SK,Salah Z,Khawaled S,Aqeilan RI.Characterization of WWOX inactivation in murine mammary gland development.J Cell Physiol.
35. Guler G,Uner A,Guler N,Han SY,Iliopoulos D,Hauck WW,McCue P,Huebner K.The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.Cancer. 2004;100:1605-14.
36. Driouch K,Prydz H,Monese R,Johansen H,Lidereau R,Frengen E.Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors.Oncogene. 2002;21:1832-40.
37. Bednarek AK,Keck-Waggoner CL,Daniel RL,Laflin KJ,Bergsagel PL,Kiguchi K,Brenner AJ,Aldaz CM.WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.Cancer Res. 2001;61:8068-73.
38. Aqeilan RI,Palamarchuk A,Weigel RJ,Herrero JJ,Pekarsky Y,Croce CM.Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor.Cancer Res. 2004;64:8256-61.
39. Huebner K,Croce CM.Cancer and the FRA3B/FHIT fragile locus: it's a HIT.Br J Cancer. 2003;88:1501-6.
40. Guler G,Uner A,Guler N,Han SY,Iliopoulos D,McCue P,Huebner K.Concordant loss of fragile gene expression early in breast cancer development.Pathol Int. 2005;55:471-8.
41. Guler G,Himmetoglu C,Jimenez RE,Geyer SM,Wang WP,Costinean S,Pilarski RT,Morrison C,Suren D,Liu J,Chen J,Kamal J,Shapiro CL,Huebner K.Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features.Breast Cancer Res Treat. 2011;129:421-32.
42. Aqeilan RI,Donati V,Gaudio E,Nicoloso MS,Sundvall M,Korhonen A,Lundin J,Isola J,Sudol M,Joensuu H,Croce CM,Elenius K.Association of Wwox with ErbB4 in breast cancer.Cancer Res. 2007;67:9330-36.
43. Putti TC,El-Rehim DM,Rakha EA,Paish CE,Lee AH,Pinder SE,Ellis IO.Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis.Mod Pathol. 2005;18:26-35.
44. Nunez MI,Ludes-Meyers J,Abba MC,Kil H,Abbey NW,Page RE,Sahin A,Klein-Szanto AJ,Aldaz CM.Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status.Breast Cancer Res Treat. 2005;89:99-105.
45. Pluciennik E,Kusinska R,Potemski P,Kubiak R,Kordek R,Bednarek AK.WWOX-the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis.Eur J Surg Oncol. 2006;32:153-7.
46. Wang X,Chao L,Ma G,Chen L,Zang Y,Sun J.The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype.J Cancer Res Clin Oncol. 2011;137:271-8.
47. Guler G,Iliopoulos D,Guler N,Himmetoglu C,Hayran M,Huebner K.Wwox and Ap2gamma expression levels predict tamoxifen response.Clin Cancer Res. 2007;13:6115-21.
48. Gothlin Eremo A,Wegman P,Stal O,Nordenskjold B,Fornander T,Wingren S.Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients.Oncol Rep. 2013;29:1467-74.
49. Jemal A,Bray F,Center MM,Ferlay J,Ward E,Forman D.Global cancer statistics.CA Cancer J Clin. 2011;61:69-90.
50. Qin HR,Iliopoulos D,Nakamura T,Costinean S,Volinia S,Druck T,Sun J,Okumura H,Huebner K.Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling.Mol Cancer Res. 2007;5:957-65.
51. Hong Q,Sze CI,Lin SR,Lee MH,He RY,Schultz L,Chang JY,Chen SJ,Boackle RJ,Hsu LJ,Chang NS.Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells.PloS One. 2009;4:e5755-e5755.
52. Watson JE,Doggett NA,Albertson DG,Andaya A,Chinnaiyan A,van Dekken H,Ginzinger D,Haqq C,James K,Kamkar S,Kowbel D,Pinkel D,Schmitt L,Simko JP,Volik S,Weinberg VK,Paris PL,Collins C.Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer.Oncogene. 2004;23:3487-94.
53. Lange EM,Beebe-Dimmer JL,Ray AM,Zuhlke KA,Ellis J,Wang Y,Walters S,Cooney KA.Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23.Prostate. 2009;69:385-91.
54. Cheng I,Levin AM,Tai YC,Plummer S,Chen GK,Neslund-Dudas C,Casey G,Rybicki BA,Witte JS.Copy number alterations in prostate tumors and disease aggressiveness.Genes Chromosomes Cancer. 2012;51:66-76.
55. Donati V,Fontanini G,Dell'Omodarme M,Prati MC,Nuti S,Lucchi M,Mussi A,Fabbri M,Basolo F,Croce CM,Aqeilan RI.WWOX expression in different histologic types and subtypes of non-small cell lung cancer.Clin Cancer Res. 2007;13:884-91.
56. Zhou Y,Xu Y,Zhang Z.Deletion and mutation of WWOX exons 6-8 in human non-small cell lung cancer.J Huazhong Univ Sci Technol Med Sci. 2005;25:162-5.
57. Baykara O,Demirkaya A,Kaynak K,Tanju S,Toker A,Buyru N.WWOX gene may contribute to progression of non-small-cell lung cancer (NSCLC).Tumour Biol. 2010;31:315-20.
58. Zhou YL,Li YC,Shou F,Liu CQ,Pu Y,Tang H.Reversing effect of exogenous WWOX gene expression on malignant phenotype of primary cultured lung carcinoma cells.Chin Med J. 2010;123:615-20.
59. Huang D,Qiu F,Yang L,Li Y,Cheng M,Wang H,Ma G,Wang Y,Hu M,Ji W,Zhou Y,Lu J.The polymorphisms and haplotypes of WWOX gene are associated with the risk of lung cancer in southern and eastern Chinese populations.Mol Carcinog.
60. Yang L,Liu B,Huang B,Deng J,Li H,Yu B,Qiu F,Cheng M,Wang H,Yang R,Yang X,Zhou Y,Lu J.A functional copy number variation in the WWOX gene is associated with lung cancer risk in Chinese.Hum Mol Genet.
61. Cantor JP,Iliopoulos D,Rao AS,Druck T,Semba S,Han SY,McCorkell KA,Lakshman TV,Collins JE,Wachsberger P,Friedberg JS,Huebner K.Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity.International journal of cancer. J Int Cancer. 2007;120:24-31.
62. Fabbri M,Garzon R,Cimmino A,Liu Z,Zanesi N,Callegari E,Liu S,Alder H,Costinean S,Fernandez-Cymering C,Volinia S,Guler G,Morrison CD,Chan KK,Marcucci G,Calin GA,Huebner K,Croce CM.MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.Proc Natl Acad Sci U S A. 2007;104:15805-10.
63. Kimura M,Takenobu H,Akita N,Nakazawa A,Ochiai H,Shimozato O,Fujimura Y,Koseki H,Yoshino I,Kimura H,Nakagawara A,Kamijo T.Bmi1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells.Cancer Sci. 2011;102:983-90.
64. Gereige R,Kumar M.Bone lesions: benign and malignant.Pediatr Rev. 2010;31:355-62.
65. Kurek KC,Del Mare S,Salah Z,Abdeen S,Sadiq H,Lee SH,Gaudio E,Zanesi N,Jones KB,DeYoung B,Amir G,Gebhardt M,Warman M,Stein GS,Stein JL,Lian JB,Aqeilan RI.Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.Cancer Res. 2010;70:5577-86.
66. Abdeen SK,Del Mare S,Hussain S,Remaileh MA,Salah Z,Hagan J,Rawahneh M,Pu XA,Russell S,Stein JL,Stein GS,Lian JB,Aqeilan RI.Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype.J Cell Physiol.
67. Yang J,Cogdell D,Yang D,Hu L,Li H,Zheng H,Du X,Pang Y,Trent J,Chen K,Zhang W.Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma.Cancer Lett. 2010;291:31-8.
68. Diniz MG,Borges ER,Pimenta FJ,De Mesquita Netto AC,De Marco L,Gomez RS,Gomes CC.Evidence of molecular alterations in the tumour suppressor gene WWOX in benign and malignant bone related lesions of the jaws.Oncol Rep. 2011;25:499-502.
69. Aqeilan RI,Hassan MQ,de Bruin A,Hagan JP,Volinia S,Palumbo T,Hussain S,Lee SH,Gaur T,Stein GS,Lian JB,Croce CM.The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism.J Biol Chem. 2008;283:21629-39.
70. Nathan SS,Pereira BP,Zhou YF,Gupta A,Dombrowski C,Soong R,Pho RW,Stein GS,Salto-Tellez M,Cool SM,van Wijnen AJ.Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma.Mol Biol Rep. 2009;36:153-8.
71. Del Mare S,Kurek KC,Stein GS,Lian JB,Aqeilan RI.Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma.Am J Cancer Res. 2011;1:585-94.
72. Mayo SC,Nathan H,Cameron JL,Olino K,Edil BH,Herman JM,Hirose K,Schulick RD,Choti MA,Wolfgang CL,Pawlik TM.Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent.Cancer. 2012;118:2674-81.
73. Kuroki T,Yendamuri S,Trapasso F,Matsuyama A,Aqeilan RI,Alder H,Rattan S,Cesari R,Nolli ML,Williams NN,Mori M,Kanematsu T,Croce CM.The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis.Clin Cancer Res. 2004;10:2459-65.
74. Nakayama S,Semba S,Maeda N,Aqeilan RI,Huebner K,Yokozaki H.Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells.Cancer Sci. 2008;99:1370-76.
75. Bloomston M,Kneile J,Butterfield M,Dillhoff M,Muscarella P,Ellison EC,Melvin WS,Croce CM,Pichiorri F,Huebner K,Frankel WL.Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features.Ann Surg Oncol. 2009;16:2331-8.
76. Nakayama S,Semba S,Maeda N,Matsushita M,Kuroda Y,Yokozaki H.Hypermethylation-mediated reduction of WWOX expression in intraductal papillary mucinous neoplasms of the pancreas.Br J Cancer. 2009;100:1438-43.
77. Maeda N,Semba S,Nakayama S,Yanagihara K,Yokozaki H.Loss of WW domain-containing oxidoreductase expression in the progression and development of gastric carcinoma: clinical and histopathologic correlations.Virchows Arch. 2010;457:423-32.
78. Yan J,Zhang M,Zhang J,Chen X,Zhang X.Helicobacter pylori infection promotes methylation of WWOX gene in human gastric cancer.Biochem Biophys Res Commun. 2011;408:99-102.
79. Takeuchi T,Adachi Y,Nagayama T.A WWOX-binding molecule, transmembrane protein 207, is related to the invasiveness of gastric signet-ring cell carcinoma.Carcinogenesis. 2012;33:548-54.
80. Aqeilan RI,Hagan JP,Aqeilan HA,Pichiorri F,Fong LY,Croce CM.Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo.Cancer Res. 2007;67:5606-10.
81. Nunez MI,Rosen DG,Ludes-Meyers JH,Abba MC,Kil H,Page R,Klein-Szanto AJ,Godwin AK,Liu J,Mills GB,Aldaz CM.WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome.BMC Cancer. 2005;5:64-64.
82. Gourley C,Paige AJ,Taylor KJ,Scott D,Francis NJ,Rush R,Aldaz CM,Smyth JF,Gabra H.WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear.Int J Oncol. 2005;26:1681-9.
83. Xiong Z,Hu S,Wang Z.Cloning of WWOX gene and its growth-inhibiting effects on ovarian cancer cells.J Huazhong Univ Sci Technol Med Sci. 2010;30:365-9.
84. Lan C,Chenggang W,Yulan B,Xiaohui D,Junhui Z,Xiao W.Aberrant expression of WWOX protein in epithelial ovarian cancer: a clinicopathologic and immunohistochemical study.Int J Gynecol Pathol. 2012;31:125-32.
85. Paige AJ,Zucknick M,Janczar S,Paul J,Mein CA,Taylor KJ,Stewart M,Gourley C,Richardson S,Perren T,Ganesan TS,Smyth JF,Brown R,Gabra H.WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.Eur J Cancer. 2010;46:818-25.
86. Yan HC,Zhang J.Effects of sodium valproate on the growth of human ovarian cancer cell line HO8910.Asian Pacific J Cancer Prev. 2012;13:6429-33.
87. Boni R,Schuster C,Nehrhoff B,Burg G.Epidemiology of skin cancer.Neuro endocrinol Lett. 2002;23(Suppl 2):48-51.
88. Lai FJ,Cheng CL,Chen ST,Wu CH,Hsu LJ,Lee JY,Chao SC,Sheen MC,Shen CL,Chang NS,Sheu HM.WOX1 is essential for UVB irradiation-induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squamous cell carcinoma in vivo.Clin Cancer Res. 2005;11:5769-77.
89. Tsai CW,Lai FJ,Sheu HM,Lin YS,Chang TH,Jan MS,Chen SM,Hsu PC,Huang TT,Huang TC,Sheen MC,Chen ST,Chang WC,Chang NS,Hsu LJ.WWOX suppresses autophagy for inducing apoptosis in methotrexate-treated human squamous cell carcinoma.Cell Death Dis. 2013;4:e792-e792.
90. Jenner MW,Leone PE,Walker BA,Ross FM,Johnson DC,Gonzalez D,Chiecchio L,Dachs Cabanas E,Dagrada GP,Nightingale M,Protheroe RK,Stockley D,Else M,Dickens NJ,Cross NC,Davies FE,Morgan GJ.Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.Blood. 2007;110:3291-300.
91. Zaidi SK,van Wijnen AJ,Lian JB,Stein JL,Stein GS.Targeting deregulated epigenetic control in cancer: cancer epigenomics as a platform for risk assessment, early detection, targeted therapy and potential for relapse.J Cell Physiol.
92. Cancer Genome Atlas Research N, Genome sequencing centres,Broad I,Getz G,Gabriel SB,Cibulskis K,Lander E,Sivachenko A,Sougnez C,Lawrence M,Washington University in St L,Kandoth C,Dooling D,Fulton R,Fulton L,Kalicki-Veizer J,McLellan MD,O'Laughlin M,Schmidt H,Wilson RK,Ye K,Ding L,Mardis ER.Cancer A,Ally A,Balasundaram M,Birol I,Butterfield YS,Carlsen R,Carter C,Chu A,Chuah E,Chun HJ,Dhalla N,Guin R,Hirst C,Holt RA,Jones SJ,Lee D,Li HI,Marra MA,Mayo M,Moore RA,Mungall AJ,Plettner P,Schein JE,Sipahimalani P,Tam A,Varhol RJ,Gordon Robertson A,Broad I,Cherniack AD,Pashtan I,Saksena G,Onofrio RC,Schumacher SE,Tabak B,Carter SL,Hernandez B,Gentry J,Salvesen HB,Ardlie K,Getz G,Winckler W,Beroukhim R,Gabriel SB,Meyerson M,Harvard Medical SB,Women's Hospital MDACC,Hadjipanayis A,Lee S,Mahadeshwar HS,Park P,Protopopov A,Ren X,Seth S,Song X,Tang J,Xi R,Yang L,Zeng D,Kucherlapati R,Chin L,Zhang J,University of North C,Todd Auman J,Balu S,Bodenheimer T,Buda E,Neil Hayes D,Hoyle AP,Jefferys SR,Jones CD,Meng S,Mieczkowski PA,Mose LE,Parker JS,Perou CM,Roach J,Shi Y,Simons JV,Soloway MG,Tan D,Topal MD,Waring S,Wu J,Hoadley KA,University of Southern C,Johns H,Baylin SB,Bootwalla MS,Lai PH,Triche TJ,Van Den Berg DJ,Weisenberger DJ,Laird PW,Shen H.Broad I,Chin L,Zhang J,Getz G,Cho J,Dicara D,Frazer S,Heiman D,Jing R,Lin P,Mallard W,Stojanov P,Voet D,Zhang H,Zou L,Noble M,Lawrence M,Institute for Systems B,Reynolds SM,Shmulevich I,Memorial Sloan-Kettering Cancer C,Arman Aksoy B,Antipin Y,Ciriello G,Dresdner G,Gao J,Gross B,Jacobsen A,Ladanyi M,Reva B,Sander C,Sinha R,Onur Sumer S,Taylor BS,Cerami E,Weinhold N,Schultz N,Shen R,University of California SCBI,Benz S,Goldstein T,Haussler D,Ng S,Szeto C,Stuart J,Benz CC,Yau C,University of Texas MDACC,Zhang W,Annala M,Broom BM,Casasent TD,Ju Z,Liang H,Liu G,Lu Y,Unruh AK,Wakefield C,Weinstein JN,Zhang N,Liu Y,Broaddus R,Akbani R,Mills GB.Nationwide Children's H,Adams C,Barr T,Black AD,Bowen J,Deardurff J,Frick J,Gastier-Foster JM,Grossman T,Harper HA,Hart-Kothari M,Helsel C,Hobensack A,Kuck H,Kneile K,Leraas KM,Lichtenberg TM,McAllister C,Pyatt RE,Ramirez NC,Tabler TR,Vanhoose N,White P,Wise L,Zmuda E,Tissue source sites A,Barnabas N,Berry-Green C,Blanc V,Boice L,Button M,Farkas A,Green A,Mackenzie J,Nicholson D,British Columbia Cancer A,Kalloger SE,Blake Gilks C,Cedars-Sinai Medical C,Karlan BY,Lester J,Orsulic S,Christiana C,Borowsky M,Cadungog M,Czerwinski C,Huelsenbeck-Dill L,Iacocca M,Petrelli N,Rabeno B,Witkin G,Cureline,Nemirovich-Danchenko E,Potapova O,Rotin D,Duke U,Berchuck A,Gynecologic Oncology G,Birrer M,Disaia P,Monovich L,International Genomics C,Curley E,Gardner J,Mallery D,Penny R,Mayo C,Dowdy SC,Winterhoff B,Dao L,Gostout B,Meuter A,Teoman A,Memorial Sloan-Kettering Cancer C,Dao F,Olvera N,Bogomolniy F,Garg K,Soslow RA,Levine DA.Abramov M,Ontario Tumour B,Bartlett JM,Kodeeswaran S,Parfitt J,St Petersburg Academic U,Moiseenko F,University Health N,Clarke BA,University of H,Goodman MT,Carney ME,Matsuno RK,University of North C,Fisher J,Huang M,Rathmell WK,Thorne L,Van Le L,University of P,Dhir R,Edwards R,Elishaev E,Zorn K,University of Texas MDACC,Broaddus R,Washington University School of M,Goodfellow PJ,Mutch D.Schultz N,Liu Y,Akbani R,Cherniack AD,Cerami E,Weinhold N,Shen H,Hoadley KA,Kahn AB,Bell DW,Pollock PM,Wang C,DAW,Shinbrot E,Karlan BY,Berchuck A,Dowdy SC,Winterhoff B,Goodman MT,Gordon Robertson A,Beroukhim R,Pashtan I,Salvesen HB,Laird PW,Noble M,Stuart J,Ding L,Kandoth C,Blake Gilks C,Soslow RA,Goodfellow PJ,Mutch D,Broaddus R,Zhang W,Mills GB,Kucherlapati R,Mardis ER,Levine DA.Ayala B,Chu AL,Jensen MA,Kothiyal P,Pihl TD,Pontius J,Pot DA,Snyder EE,Srinivasan D,Kahn AB.National Cancer I,Mills Shaw KR,Sheth M,Davidsen T,Eley Martin LFG,Demchok JA,Yang L,National Human Genome Research I,Guyer MS,Ozenberger BA,Sofia HJ,Writing c,Kandoth C,Schultz N,Cherniack AD,Akbani R,Liu Y,Shen H,Gordon Robertson A,Pashtan I,Shen R,Benz CC,Yau C,Laird PW,Ding L,Zhang W,Mills GB,Kucherlapati R,Mardis ER,Levine DA.Integrated genomic characterization of endometrial carcinoma.Nature. 2013;497:67-73.
93. Park SW,Ludes-Meyers J,Zimonjic DB,Durkin ME,Popescu NC,Aldaz CM.Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma.Br J Cancer. 2004;91:753-9.
94. Aderca I,Moser CD,Veerasamy M,Bani-Hani AH,Bonilla-Guerrero R,Ahmed K,Shire A,Cazanave SC,Montoya DP,Mettler TA,Burgart LJ,Nagorney DM,Thibodeau SN,Cunningham JM,Lai JP,Roberts LR.The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.J Hepatol. 2008;49:373-83.
95. Hu BS,Tan JW,Zhu GH,Wang DF,Zhou X,Sun ZQ.WWOX induces apoptosis and inhibits proliferation of human hepatoma cell line SMMC-7721.World J Gastroenterol. 2012;18:3020-26.
96. Li YP,Wu CC,Chen WT,Huang YC,Chai CY.The expression and significance of WWOX and beta-catenin in hepatocellular carcinoma.APMIS. 2013;121:120-26.
97. Pluciennik E,Nowakowska M,Wujcicka WI,Sitkiewicz A,Kazanowska B,Zielinska E,Bednarek AK.Genetic alterations of WWOX in Wilms' tumor are involved in its carcinogenesis.Oncol Rep. 2012;28:1417-22.
98. Zelazowski MJ,Pluciennik E,Pasz-Walczak G,Potemski P,Kordek R,Bednarek AK.WWOX expression in colorectal cancer-a real-time quantitative RT-PCR study.Tumour Biol. 2011;32:551-60.
99. Dincer N,Tezel GG,Sungur A,Himmetoglu C,Huebner K,Guler G.Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland.Oral Oncol. 2010;46:195-9.
100. Kosla K,Pluciennik E,Kurzyk A,Jesionek-Kupnicka D,Kordek R,Potemski P,Bednarek AK.Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme.J Neuro-oncol. 2011;101:207-13.
101. Chiang MF,Yeh ST,Liao HF,Chang NS,Chen YJ.Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53.Biomed Pharmacother. 2012;66:433-38.
102. Ishii H,Vecchione A,Furukawa Y,Sutheesophon K,Han SY,Druck T,Kuroki T,Trapasso F,Nishimura M,Saito Y,Ozawa K,Croce CM,Huebner K,Furukawa Y.Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.Mol Cancer Res. 2003;1:940-47.
103. Cui Z,Lin D,Cheng F,Luo L,Kong L,Xu J,Hu J,Lan F.The role of the WWOX gene in leukemia and its mechanisms of action.Oncol Rep. 2013;29:2154-62.